Nama's AI scorecard currently rates Neurocrine Biosciences Strong Buy (8.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NBIX's P/E ratio?

Neurocrine Biosciences trades at a trailing price-to-earnings ratio of 16.5.

When does NBIX report earnings?

Neurocrine Biosciences's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $2.79.

What is the NBIX price target?

The median analyst price target from 28 analysts is $214.50, with a range of $150.00 – $253.00.

Is NBIX Shariah compliant?

Nama's AAOIFI-style screen reads Neurocrine Biosciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Neurocrine Biosciences (NBIX)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Neurocrine Biosciences (NBIX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $16.66B, a trailing price-to-earnings ratio of 16.5 and a free-cash-flow yield of 4.4%. Over the most recent reported fiscal year, revenue grew 21.4% and free cash flow per share grew 35.9%. Nama's AI scorecard rates it Strong Buy, 8.9 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Strong Buy · 8.9/10

The top band of the Fundamental Verdict (8.6–10). As of Nov 7, 2026.

Momentum

Lagging · -7.3% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-11.6%

How far the last close sits under the highest price of the past five years.

Market cap	$16.66B
Trailing P/E	16.5
Price / book	4.5
Price / sales	5.0
FCF yield	4.4%
Dividend yield	—
Gross margin	98.0%
Operating margin	23.9%
Net margin	20.9%
Revenue growth (YoY)	+21.4%
Revenue growth (3-yr annual)	+24.3%
EPS growth (YoY)	+1.1%
FCF/share growth (YoY)	+35.9%
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

NBIX earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $2.79). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$3.29	$2.75	+19.6%	$1.12B
Q2 2026	Jul 30, 2026	$2.85	$1.96	+45.4%	$959.00M
Q1 2026	May 5, 2026	$1.94	$1.70	+14.1%	$814.50M
Q4 2025	Feb 11, 2026	$1.88	$2.30	-18.3%	$805.50M

NBIX analyst price target

Median target $214.50 from 28 analysts, ranging $150.00 – $253.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live NBIX data on Nama Insights →

Recent Congressional trades

Neurocrine Biosciences trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025

NBIX FAQ

Is NBIX a buy?: Nama's AI scorecard currently rates Neurocrine Biosciences Strong Buy (8.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NBIX's P/E ratio?: Neurocrine Biosciences trades at a trailing price-to-earnings ratio of 16.5.
When does NBIX report earnings?: Neurocrine Biosciences's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $2.79.
What is the NBIX price target?: The median analyst price target from 28 analysts is $214.50, with a range of $150.00 – $253.00.
Is NBIX Shariah compliant?: Nama's AAOIFI-style screen reads Neurocrine Biosciences as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.